The imperative to share clinical study reports: recommendations from the Tamiflu experience
about
Open clinical trial data for all? A view from regulatorsOpenTrials: towards a collaborative open database of all available information on all clinical trialsDifferences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentinCompleteness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available dataComplaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulationReporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic ReviewClinical research data sharing: what an open science world means for researchers involved in evidence synthesisUK publicly funded Clinical Trials Units supported a controlled access approach to share individual participant data but highlighted concernsHow should individual participant data (IPD) from publicly funded clinical trials be shared?Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine TrialIncreasing value and reducing waste: addressing inaccessible researchWho has used internal company documents for biomedical and public health research and where did they find them?Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusionSPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trialsA Narrative Review of Influenza: A Seasonal and Pandemic Disease.Evidence-informed person-centered healthcare part I: do 'cognitive biases plus' at organizational levels influence quality of evidence?Why do we need systematic reviews to inform healthcare decisions in the disaster context.Orchestrating differential data access for translational research: a pilot implementation.Access to regulatory data from the European Medicines Agency: the times they are a-changing.Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional studyPromises and pitfalls of data sharing in qualitative research.Secrecy or transparency? The future of regulatory trial data.Methodological developments in searching for studies for systematic reviews: past, present and future?Regulating prescription drugs for patient safety: does Bill C-17 go far enough?Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.Guidelines in the Register of the Association of Scientific Medical Societies in Germany - A Quality Improvement Campaign.Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reportsConflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles.Getting more generous with the truth: clinical trial reporting in 2013 and beyond.Blood pressure lowering efficacy of renin inhibitors for primary hypertension.Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.Against vaccine assay secrecy.Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reportsIndustry influence in evidence productionRestoring invisible and abandoned trials: a call for people to publish the findings.Pharmacogenomics in clinical practice and drug development.Transparency in Europe: A Quantitative Study.The evolution in registration of clinical trials: a chronicle of the historical calls and current initiatives promoting transparency.Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trialsPharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.
P2860
Q21144613-825F236B-C60D-4712-B21A-4164BB0A0FECQ26834199-C0099260-6E0A-40CE-B20A-C82A23598935Q28485343-FBF45507-D496-4815-ACD3-37BAAF5BFBC4Q28534273-8F8EE860-0A56-4174-AA15-449822C92B0CQ28543449-00A5334E-267C-484C-98D9-A0D04948CC6FQ28554247-86D930F2-A9CC-46A9-B231-1AF4D893B549Q28595531-42656D31-4E60-4513-AE08-86AE5CA17936Q28601297-C1165A5D-77E0-4CDE-9BCC-76F7A5B2EC8CQ28604049-D3D0863A-ADB3-4ECA-B6C3-AB1F758A77A0Q28607942-3504E214-892C-4303-9CF1-8C187F7369B2Q28611347-B326BF44-F8F1-4121-AF97-1D7C8364A8BEQ28657906-37962E7A-6593-4C9F-8319-BF532CAB7FD2Q28681258-08AF251F-A020-4B54-9626-55DFF46F8A75Q28710019-AF1F00EF-DFB6-46BA-AA5A-3D44E96D437EQ30235281-744D6DFA-4CE0-4B85-9F9C-6DC288BA2AC4Q30368983-A8F8B445-5ECD-4FCB-AAE7-1E11E842E2E8Q30374505-A20EF916-03B1-416F-B0DD-BFD35255AF6EQ30491200-0CB0FB47-ED3B-4F36-BB99-BE79324155D7Q30575381-74B287E1-0B89-4379-818D-410B00F7436EQ30583430-EE9B48DB-A468-4EF5-BA1E-7DFA997B66C3Q31122209-FAE0EA8F-5A4E-43CB-B0FA-26B6B39B92F5Q31168157-619736A9-6018-4969-A818-879D998A755AQ33590254-BCA27703-B054-499D-91A3-4525C8FB05DBQ33590650-36FFC5DE-0D9E-44D8-BB0F-AE524CC38954Q33815256-34C694A3-E616-4C39-B2CC-2892779FB917Q33932009-9D1BBD66-0250-4798-BF37-6E0A209DDEB6Q34264254-1315BE45-B97E-4887-84F1-FF7D98405B6FQ34560163-C82B7627-867A-4ED4-B364-2A68FD6B1915Q34574783-FB51ED12-BE41-4CAA-9024-88006125946FQ34681386-FD68020E-BAFF-4A64-8998-5E4D7C7F3CE4Q35716074-A2B2549F-AFBD-4C2E-A1C2-4A4FEB4D13C6Q35887486-A886730A-0241-49C3-81FE-B1B0364099F0Q36650066-54631D48-CAB2-4342-B41A-0C1F6E3FAC64Q36920494-7AF7285E-B05D-4154-A8A3-45DB9285BA48Q36937327-1F53A60C-93D0-4701-A57C-A5D0274602C7Q37284234-F240DF36-6A02-4C68-BC4F-59A096F8F78AQ38452513-6DC6DDA8-925F-46A1-A9E5-F3B8DBBC1730Q38560675-4B7BE7F9-5618-41C6-A242-9EDF836D160CQ38814635-F0169CB7-FAA1-4E27-86E5-6B13BBE15BD0Q38981425-583871B3-659B-49D4-B808-28FFAEBD0804
P2860
The imperative to share clinical study reports: recommendations from the Tamiflu experience
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The imperative to share clinic ...... ns from the Tamiflu experience
@ast
The imperative to share clinic ...... ns from the Tamiflu experience
@en
The imperative to share clinic ...... ns from the Tamiflu experience
@en-gb
The imperative to share clinic ...... ns from the Tamiflu experience
@nl
type
label
The imperative to share clinic ...... ns from the Tamiflu experience
@ast
The imperative to share clinic ...... ns from the Tamiflu experience
@en
The imperative to share clinic ...... ns from the Tamiflu experience
@en-gb
The imperative to share clinic ...... ns from the Tamiflu experience
@nl
altLabel
The Imperative to Share Clinic ...... ns from the Tamiflu Experience
@en
prefLabel
The imperative to share clinic ...... ns from the Tamiflu experience
@ast
The imperative to share clinic ...... ns from the Tamiflu experience
@en
The imperative to share clinic ...... ns from the Tamiflu experience
@en-gb
The imperative to share clinic ...... ns from the Tamiflu experience
@nl
P2860
P3181
P1433
P1476
The imperative to share clinic ...... ns from the Tamiflu experience
@en
P2093
Peter Doshi
Tom Jefferson
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1001201
P407
P577
2012-01-01T00:00:00Z